NCT01164007View on ClinicalTrials.gov

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Malignant Melanoma
Interventions
DRUG

Bevacizumab

Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.

DRUG

Dacarbazine

Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.

Trial Locations (1)

20141

Istituto Europeo Di Oncologia, Milan

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01164007 - A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | Biotech Hunter | Biotech Hunter